Physician profile
Joseph Ramek
NPI 1992880090
$9,518.68
in general payments reported to CMS, 2019-2025
23 companies · $1,049 in 2025
The $1,049 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,290 · 2020: $1,999 · 2021: $1,651 · 2022: $380 · 2023: $1,758 · 2024: $1,391 · 2025: $1,049.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,913 · Food and Beverage: $915 · Long Term Medical Supply Or Device Loan: $682 · Education: $286 · Honoraria: $259 · Travel and Lodging: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,912.50 |
| Food and Beverage | $915.46 |
| Long Term Medical Supply Or Device Loan | $681.53 |
| Education | $285.89 |
| Honoraria | $259.36 |
| Travel and Lodging | $143.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,956.29 | 2023-2024 | Imfinzi |
| Tg Therapeutics, INC. | $1,526.25 | 2021 | |
| Celgene Corporation | $1,498.53 | 2020-2023 | Pomalyst |
| Novartis Pharmaceuticals Corporation | $1,073.58 | 2019-2025 | |
| Abbvie INC. | $844.41 | 2019 | |
| Glaxosmithkline, LLC. | $595.24 | 2020-2025 | Ojjaara |
| Alexion Pharmaceuticals, INC. | $331.03 | 2019-2025 | Ultomiris |
| Karyopharm Therapeutics INC. | $271.49 | 2025 | Xpovio |
| Janssen Biotech, INC. | $228.97 | 2019-2025 | Talvey, Darzalex, Tecvayli |
| Incyte Corporation | $185.94 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $152.26 | 2019-2025 | Reblozyl |
| Athenex Pharmaceutical Division, LLC | $150.00 | 2020 | |
| Pharmacosmos Therapeutics INC. | $143.60 | 2023 | Monoferric |
| Sobi, INC | $99.95 | 2023 | |
| Genzyme Corporation | $88.75 | 2019-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $68.09 | 2024-2025 | Myrisk |
| Bayer Healthcare Pharmaceuticals INC. | $63.04 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $62.82 | 2019-2025 | Keytruda, Lynparza |
| Beone Medicines USA, INC. | $47.87 | 2025 | Brukinsa |
| Pfizer INC. | $40.67 | 2019 | |
| Genentech USA, INC. | $38.97 | 2019 | |
| Geron Corporation | $26.85 | 2025 | Rytelo |
| Mylan Institutional INC. | $24.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Ramek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.